SCHEMBL16762223

SCHEMBL16762223

N=C1NC(=O)/C(=C\c2ccc3oc4ccccc4c3c2)S1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ XDH P47989 3/20 0.53
▸ MEN1 O00255 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ MRE11 P49959 1/20 0.52
▸ CLK1 P49759 1/20 0.52
▸ CLK2 P49760 1/20 0.52
▸ CLK3 P49761 1/20 0.52
▸ DYRK1A Q13627 1/20 0.52
▸ DYRK1B Q9Y463 1/20 0.52
▸ POLB P06746 2/20 0.49
▸ PIP4K2A P48426 1/20 0.45
▸ GSK3A P49840 3/20 0.45
▸ GSK3B P49841 3/20 0.45
▸ PIM1 P11309 3/20 0.44
▸ PIM2 Q9P1W9 2/20 0.44
▸ PIM3 Q86V86 1/20 0.44
▸ RAB9A P51151 1/20 0.42
▸ PIP4K2B P78356 1/20 0.42
▸ CDK2 P24941 1/20 0.42
▸ MAOA P21397 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16762221 1.00 XDH (0.53) XDHMEN1KMT2AMRE11CLK1
SCHEMBL16762254 0.85 PIM1 (0.61) MEN1KMT2APIM1RAB9ACISD1
SCHEMBL16762252 0.85 PIM1 (0.61) MEN1KMT2APIM1RAB9ACISD1
SCHEMBL16762257 0.85 PIM1 (0.61) MEN1KMT2APIM1RAB9ACISD1
SCHEMBL16998371 0.80 SMN1; SMN2 (0.37) MEN1KMT2APIM1PIM2PIM3
SCHEMBL19697343 0.77 MEN1 (0.40) MEN1KMT2ADYRK1ADYRK1BGSK3B
SCHEMBL16998370 0.75 RAB9A (0.37) MEN1KMT2APIM1RAB9AMAOA
SCHEMBL22971852 0.75 XDH (0.75) XDHMEN1KMT2AMRE11CLK1
SCHEMBL16762261 0.74 MEN1 (0.55) XDHMEN1KMT2AMRE11CLK1
SCHEMBL16762263 0.74 MEN1 (0.55) XDHMEN1KMT2AMRE11CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2881397-B1 COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR UNIV KYOTO (JP) 2020-09-02 — — EP disclosed
US-10017524-B2 Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor KYOTO UNIVERSITY (JP) 2018-07-10 — — US disclosed
US-20170355715-A1 COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR KYOTO UNIVERSITY (JP) 2017-12-14 — — US disclosed
US-9745323-B2 Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor KYOTO UNIVERSITY (JP) 2017-08-29 — — US disclosed
US-20150225421-A1 COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR KYOTO UNIVERSITY (JP) 2015-08-13 — — US disclosed
EP-2881397-A1 COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR Kyoto University (JP) 2015-06-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225421-A1 COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR VHL, TP53, COMT XDH 2640/4885MEN1 31/4885KMT2A 277/4885
US-20170355715-A1 COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR VHL, TP53, COMT XDH 2640/4885MEN1 31/4885KMT2A 277/4885
US-10017524-B2 Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor VHL, TP53, COMT XDH 2640/4885MEN1 31/4885KMT2A 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback